Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020;2(10):1707-1708.
doi: 10.1007/s42399-020-00462-2. Epub 2020 Aug 21.

Potential Interactions of Remdesivir with Pulmonary Drugs: a Covid-19 Perspective

Zainab Gandhi  1 , Zeeshan Mansuri  2 , Snehal Bansod  3
Affiliations

Potential Interactions of Remdesivir with Pulmonary Drugs: a Covid-19 Perspective

Zainab Gandhi et al. SN Compr Clin Med. 2020.

Abstract

In this letter, we discuss the potential interactions of remdesivir, the newly approved Covid-19 drug with pulmonary medications. These interactions have been summarized keeping the busy clinician in mind. While remdesivir has proven to be a safe medication generally, we here have enlisted the potential interactions of remdesivir that a clinician needs to be mindful of while prescribing the medication.

Keywords: Drug interactions; Pulmonology; Remdesivir.

PubMed Disclaimer

Conflict of interest statement

Conflict of InterestThe authors declare that they have no conflict of interest.

References

    1. Tchesnokov E, et al. Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses. 2019;11(4):326. doi: 10.3390/v11040326. - DOI - PMC - PubMed
    1. Crisci CD, Ardusso L, Mossuz A, Müller L. A precision medicine approach to SARS-CoV-2 pandemic management. Curr Treat Options Allergy. 2020:1–19. Advance online publication. 10.1007/s40521-020-00258-8. - PMC - PubMed
    1. Di Sanzo M, Cipolloni L, Borro M, et al. Clinical applications of personalized medicine: a new paradigm and challenge. Curr Pharm Biotechnol. 2017;18(3):194–203. doi: 10.2174/1389201018666170224105600. - DOI - PubMed
    1. McCreary EK, Pogue JM. Coronavirus disease 2019 treatment: a review of early and emerging options. Open Forum Infect Dis. 2020;7(4):ofaa105. doi: 10.1093/ofid/ofaa105. - DOI - PMC - PubMed
    1. Singh AK, et al. Remdesivir in COVID-19: a critical review of pharmacology, pre-clinical and clinical studies. Diabetes Metab Syndr Clin Res Rev. 2020;14(4):641–648. doi: 10.1016/j.dsx.2020.05.018. - DOI - PMC - PubMed

LinkOut - more resources